AVRX Avalon Pharmaceuticals (MM)

Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it is scheduled to release financial results for the fourth quarter and full year of 2007 on Wednesday, March 19, 2008 after the close of the U.S. financial markets. The Company will also host a conference call on Thursday, March 20, 2008 at 8:30 a.m. Eastern Time to discuss its business and financial results, as well as future expectations. Interested investors, analysts, members of the media and the general public can listen to the call live over the Internet or by dialing the numbers listed below. Conference Call details: Dial-In: (888) 287-5529 (U.S.) (719) 457-2088 (International) Passcode: 5811984 � Webcast: Please visit the Investor Presentations section of Avalon Pharmaceuticals' website, http://www.avalonrx.com. � The conference call replay will be available for 30 days. About Avalon Pharmaceuticals Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon�s lead product candidate, AVN944,�an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways,�discovery programs�for�inhibitors of�the Survivin�and Myc�pathways and partnerships with Merck, MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx� is the company�s proprietary platform�which is based on�large-scale�biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, MD.